United BioSource Corporation's (UBC) Annette Stemhagen, DrPH, FISPE, and Gerald Faich, MD, MPH, FISPE, addressed the Risk Management and Drug Safety Summit held in Washington, DC, on October 28 and 29, along with Janet Woodcock, MD, Director, CDER, FDA; Jane Axelrad, Associate Director for Policy, CDER, FDA; Claudia Karwoski, acting director, Division of Risk Management Team, Office of Surveillance and Epidemiology, CDER; and other leading scientists from the pharmaceutical community.

United BioSource Corporation (UBC) today announces that on July 28, 2008, it entered into a strategic partnership with CogState Ltd. to increase the ability for pharmaceutical and life sciences companies to conduct cognitive testing in clinical trials. Customers will be able to leverage both companies’ scientific resources, software capabilities and global operations to support full-scale clinical development programs.

United BioSource Corporation (UBC) today announced the acquisition of Envision Pharma, a leading scientific communications and technology company. Envision integrates scientific communication services and targeted software applications that contribute to marketplace awareness and comprehension of compounds at launch and beyond.

To offer clients cutting-edge thinking in study methodology for CNS clinical trials, United BioSource Corporation (UBC) announces the formation of a European Advisory Board for CNS Clinical Trials. This Advisory Board was established to support UBC in its ongoing efforts to improve data quality and outcomes in CNS trials that rely on subjective measurements as pivotal endpoints, such as those in psychiatry, neurology and pain. Recommendations of this Board will be integrated into UBC’s customized training and validated assessment programs targeting investigators and study personnel.

United BioSource Corporation (UBC) today announced the expansion of its Regulatory Affairs group led by distinguished experts Mark Ammann, PharmD and LaVonne Lang, DrPH. Based in Ann Arbor, Michigan, the group will provide a full range of services to pharmaceutical and biotechnology clients, including creating and implementing development plans to fulfill regulatory requirements for initial approval of new medicines and providing life-cycle management for marketed products.

United BioSource Corporation's (UBC) director of global health economics has just delivered to the German government one of the most significant revisions of drug policy produced in Europe in more than a decade.